ISB-1302 is under clinical development by Ichnos Sciences and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISB-1302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISB-1302 (GBR-1302) is under development for the treatment of HER2 positive breast cancer. The drug candidate is a new biological entity, and it is administered by the intravenous and subcutaneous route. It is a bi-specific monoclonal antibody which acts by targeting HER2 and CD3. The development of the drug candidate is based on BEAT (Bi-specific Engagement by Antibodies based on the T cell receptor) antibody technology platform. It was also under development for the treatment of gastric cancer and ovarian cancer.
Ichnos Sciences overview
Ichnos Sciences is a bio pharmaceutical manufacturing company. The company is engaged in developing therapies for treating oncology and autoimmune disease. It’s technology portfolio includes BEAT (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform which uses a novel method for engineering bispecific antibodies that may treat cancers and ISB 830 is designed to block the key immune system activation factor to treat a variety of illnesses and provides an entirely novel method of action for the treatment of autoimmune disease. Ichnos Sciences is headquartered in New York, the US.
For a complete picture of ISB-1302’s drug-specific PTSR and LoA scores, buy the report here.